Skip to main content

Sandoz Group

Sandoz Group AG is a Swiss global pharmaceutical company specializing in generic prescription medicines and biosimilars, operating independently following its spinoff from Novartis. The company researches, manufactures, and markets generic oral solids, anti-infectives, complex generics, and biosimilar biologic therapeutics across oncology, immunology, and endocrinology, including Omnitrope and Hyrimoz. Main revenue drivers comprise global commercial sales of generic prescription pharmaceuticals, biosimilar biologics, and active pharmaceutical ingredients (APIs). Sandoz serves hospital networks, prescription pharmacies, healthcare authorities, and patients across Europe, North America, Asia, and Latin America. The enterprise holds a world-dominant market position as a premier global leader in generic pharmaceuticals and biosimilar therapies. Headquartered in Basel, Switzerland, Sandoz Group AG is listed on the SIX Swiss Exchange.

58 of the funds FundTelligence covers report a position in Sandoz Group.

Legal name
SANDOZ GROUP AG
Sector
Health Care
Country
Switzerland
Funds holding it
58

Funds holding Sandoz Group

Showing the 8 largest of 58 funds holding it.

Loading...